AZN vs MDWD

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

MDWD exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. The company is experiencing a catastrophic operational collapse with revenue plummeting by 68% YoY and operating margins sitting at -417.78%. While the balance sheet remains liquid with a Current Ratio of 2.33 and low debt, these are lagging indicators that cannot offset the rapid erosion of the top and bottom lines. There is a dangerous divergence between the fundamental decay and the 'Strong Buy' analyst consensus, suggesting the stock is priced on speculative hopes rather than data-driven value.